chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: FLUX
Symptoms: Allergy to vaccine, Hypersensitivity
Clinical narrative: Allergic reaction to a previous influenza vaccine; This spontaneous case was received on 14-Oct-2021 from other health professional (nurse) via Communications (reference number: SEQW21-03878) and concerned a female patient of unspecified age.  The patient's medical history and concomitant medications were not reported.  On an unspecified date, the patient was vaccinated with Influenza virus vaccine polyvalent (brand name unknown; dose, route of administration and anatomical: not reported) for prevention of seasonal influenza. The batch number was not reported.  On an unspecified date, an unknown amout of time after receiving with Influenza virus vaccine polyvalent, the patient experienced severe allergic reaction to influenza vaccine.  At the time of initial report on 14-Oct-2021, the outcome of the event was not reported.  The reporter assessed the event to be related to Influenza virus vaccine polyvalent.  The case was assessed as non-serious.  Company comment: The event of 'allergy to vaccine' is considered as unassessable to influenza virus vaccine polyvalent.; Sender's Comments: The event of 'allergy to vaccine' is considered as unassessable to influenza virus vaccine polyvalent.
Age: 77.0
Sex: F
Vaccine: FLUA4
Symptoms: Blood glucose normal, Blood pressure increased, Hyperhidrosis, Incoherent, Malaise
Clinical narrative: This spontaneous case was retrieved on 18-Oct-2021 from Vaccine Adverse Event Reporting System (VAERS) (reference number: 1713969-1), reported by other healthcare professional and concerned a 77-year-old, female patient. The patient's concurrent conditions included lung disease and doxycycline allergy. The patient's concomitant medication included clopidogrel and unspecified vitamin D, both used for unreported indications. On 19-Sep-2021, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; dose reported as one, route of administration: intramuscular (IM), anatomical location: left arm (LA) and indication: not reported). The batch number reported was 312842. On the same day, after receiving Fluad Quadrivalent, the patient did not feel well during paying for her groceries in the store. The store employees assessed her with sitting on the bench and gave her some water. The pharmacist came to assist and checked her blood pressure which was at 170/88. The patient stated that she ate her breakfast, but they gave her sip of orange juice with a straw. The patient's face had a light sweat and she was extremely drowsy and in and out of coherence. As reported, the patient could state her name and asked the employees to call her boyfriend. Also, 911 was called even the patient did not want to call 911. The first responders checked her blood sugar and it was 120 (unit and reference range were not reported). They analysed her heart with an automated external defibrillator (AED), and no shock was advised. The patient was then transported to the local hospital by the emergency medical services (EMS). The outcome of the events was unknown. The reporter did not provide a causality assessment. This case is assessed as non-serious. Company comment: A 77-year-old patient experienced somnolence, incoherence, increased blood pressure, facial swelling, and malaise on the same day, after receiving after receiving the suspect product Fluad Quadrivalent. Although clopidogrel confounds causality, it is assessed as possible, due to plausible chronology.; Sender's Comments: A 77-year-old patient experienced somnolence, incoherence, increased blood pressure, facial swelling, and malaise on the same day, after receiving after receiving the suspect product Fluad Quadrivalent. Although clopidogrel confounds causality, it is assessed as possible, due to plausible chronology.
Age: 77.0
Sex: F
Vaccine: FLUA4
Symptoms: Somnolence, Swelling face
Clinical narrative: This spontaneous case was retrieved on 18-Oct-2021 from Vaccine Adverse Event Reporting System (VAERS) (reference number: 1713969-1), reported by other healthcare professional and concerned a 77-year-old, female patient. The patient's concurrent conditions included lung disease and doxycycline allergy. The patient's concomitant medication included clopidogrel and unspecified vitamin D, both used for unreported indications. On 19-Sep-2021, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; dose reported as one, route of administration: intramuscular (IM), anatomical location: left arm (LA) and indication: not reported). The batch number reported was 312842. On the same day, after receiving Fluad Quadrivalent, the patient did not feel well during paying for her groceries in the store. The store employees assessed her with sitting on the bench and gave her some water. The pharmacist came to assist and checked her blood pressure which was at 170/88. The patient stated that she ate her breakfast, but they gave her sip of orange juice with a straw. The patient's face had a light sweat and she was extremely drowsy and in and out of coherence. As reported, the patient could state her name and asked the employees to call her boyfriend. Also, 911 was called even the patient did not want to call 911. The first responders checked her blood sugar and it was 120 (unit and reference range were not reported). They analysed her heart with an automated external defibrillator (AED), and no shock was advised. The patient was then transported to the local hospital by the emergency medical services (EMS). The outcome of the events was unknown. The reporter did not provide a causality assessment. This case is assessed as non-serious. Company comment: A 77-year-old patient experienced somnolence, incoherence, increased blood pressure, facial swelling, and malaise on the same day, after receiving after receiving the suspect product Fluad Quadrivalent. Although clopidogrel confounds causality, it is assessed as possible, due to plausible chronology.; Sender's Comments: A 77-year-old patient experienced somnolence, incoherence, increased blood pressure, facial swelling, and malaise on the same day, after receiving after receiving the suspect product Fluad Quadrivalent. Although clopidogrel confounds causality, it is assessed as possible, due to plausible chronology.
Age: 73.0
Sex: M
Vaccine: FLUA4
Symptoms: Hypersensitivity, Urticaria
Clinical narrative: This spontaneous case was retrieved on 18-Oct-2021 from Vaccine Adverse Event Reporting System (VAERS) (reference number: 1715789-1), reported by other healthcare professional and concerned a 73-year-old, male patient. The patient's relevant medical history was not reported. The patient had no known allergies. The patient's concomitant medication included Atorvastatin (atorvastatin calcium), Losartan (losartan potassium), trazodone, Pantoprazole (Pantoprazole sodium sesquihydrate) and gabapentin, all used for an unreported indication. On 14-Sep-2021, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; route of administration: intramuscular (IM), anatomical location: right arm (RA), dose: 'one' as reported and indication: not reported). The batch number reported was 312828. On the same day, after receiving Fluad Quadrivalent, the patient experienced hives all over his arms and trunk. On 18-Sep-2021, the patient came to healthcare professional (HCP) who recommended that he take some Benadryl (diphenhydramine hydrochloride) and to let his doctor know about this reaction. The HCP documented the allergy in their system as well. The outcome of the events was unknown. The reporter did not provide a causality assessment. This case is assessed as non-serious. Company comment: The events of 'hives' and 'allergy' were assessed as related to Fluad Quadrivalent.; Sender's Comments: The events of 'hives' and 'allergy' were assessed as related to Fluad Quadrivalent.
Age: 98.0
Sex: F
Vaccine: UNK
Symptoms: Headache
Clinical narrative: Headache; This spontaneous case was received on 17-Oct-2021 from other non-healthcare professional via regulatory authority (reference number: SEQW21-04037) and concerned a 98-year-old female patient.  The patient's medical history and concomitant medications were not reported.  On 07-Oct-2021, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; dose: 0.5 ml, route of administration: intramuscular and anatomical location: deltoid) for influenza prophylaxis. The batch number was not reported.  On the same day, after receiving Fluad Quad, the patient experienced the worst headache ever later that day.  On 08-Oct-2021, the patient recovered from the events.  The reporter did not provide a causality assessment.  The case was assessed as non-serious.  The case is linked with teh case 202103901 (the same reporter).  Company comment: The event of 'headache' was assessed as related to Fluad Quadrivalent.; Sender's Comments: The event of 'headache' was assessed as related to Fluad Quadrivalent.
Age: 70.0
Sex: F
Vaccine: FLUA4
Symptoms: Injection site reaction, Rash macular
Clinical narrative: Red, blotchy reaction around injection site which spread all over body; This spontaneous case was received on 17-Oct-2021 from other non-healthcare professional via The Regulatory Authority (reference number: SEQW21-04032) and concerned a 70-year-old female patient.  The patient's medical history was not reported. The patient's concomitant medications included fish oil for unreported indication.  On 07-Oct-2021, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; dose: 0.5 ml, route of administration: intramuscular and anatomical location: deltoid) for influenza prophylaxis. The batch number was not reported.  On 08-Oct-2021, one day after administration of Fluad Quadrivalent, the patient developed red, blotchy reaction around injection site which spread all over body. As reported, the patient thought she may be allergic to squalene.  On the same day, the patient took Benadryl (diphenhydramine hydrochloride) orally with no result, then went to emergency room where she received prednisone and Benadryl intravenous (IV).   On the same date, the patient recovered from the event. Reaction resolved completely by the evening, however, the patient was sent home with a prednisone taper for four days.  The reporter did not provide a causality assessment.  The case was assessed as non-serious.  The case is linked with the case 202103897 (the same reporter).  Company comment: The event of 'red blotches' was assessed as related to Fluad Quadrivalent.; Sender's Comments: The event of 'red blotches' was assessed as related to Fluad Quadrivalent.
Age: 94.0
Sex: M
Vaccine: UNK
Symptoms: Oedema, Rash, Swelling, Urticaria
Clinical narrative: Edema; Swelling; Rash; Hives; This spontaneous case was received on 18-Oct-2021 from a pharmacist via regulatory authority (reference number: SEQW21-04084) and concerned a 94-year-old, male patient.  The patient's concurrent conditions included allergy to amlodipine and pantoprazole. The patient's concomitant medications were not reported.  On 27-Sep-2021, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; dose: 0.5 ml, route of administration: intramuscular (IM) and anatomical location: deltoid) as an influenza prophylaxis. The batch number was not reported.  On 02-Oct-2021, five days after receiving Fluad Quadrivalent, the patient experienced rash, swelling, edema and hives treated with prednisone and Benadryl (diphenhydramine hydrochloride).  On an unspecified date in Oct-2021, the patient recovered from the events. As reported, the patient was fine.  The reporter assessed all events to be related to Fluad Quadrivalent. As reported, the patient showed late-onset reactions to Fluad Quadrivalent.  The reporter assessed the case as non-serious.  Company comment: A 94-year-old, male patient was vaccinated with the suspect product Fluad Quadrivalent. Five days after vaccination the patient experienced rash, swelling, oedema and hives. Information regarding the concomitant medications has not been provided. Based on plausible time relationship, causality is assessed as possibly related.; Reporter's Comments: As reported, a patient showed late-onset reactions to Fluad Quadrivalent experiencing rash, swelling, edema and hives.; Sender's Comments: A 94-year-old, male patient was vaccinated with the suspect product Fluad Quadrivalent. Five days after vaccination the patient experienced rash, swelling, oedema and hives. Information regarding the concomitant medications has not been provided. Based on plausible time relationship, causality is assessed as possibly related.
Age: 65.0
Sex: F
Vaccine: FLUA4
Symptoms: Injection site pain, Injection site rash, Injection site swelling
Clinical narrative: This spontaneous case was retrieved on 19-Oct-2021 from Vaccine Adverse Event Reporting System (VAERS) (reference number: 1734662-1), reported by other healthcare professional and concerned a 65-year-old, female patient. The patient's relevant medical history was not reported. The patient's concomitant medications included simvastatin, levothyroxine and Vitamine D (colecalciferol), all used for an unreported indication. The patient had no known allergies. On 22-Sep-2021, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; route of administration: intramuscular (IM), dose: 'one' as reported, anatomical location: left arm (LA) and indication: not reported). The batch number reported was 312832. On 23-Sep-2021, one day after receiving Fluad Quadrivalent, the patient experienced rash, swelling, burning sensation and pain on left arm that was three inches below the injection site. As reported, Tylenol (paracetamol) helped her to control the pain. On 24-Sep-2021, the patient reported symptoms. The patient was provided with Benadryl (diphenhydramine hydrochloride) and advised to start first dose of 50 mg, then to repeat if needed at a dose of 25 mg, every four to six hours (q4-6 hrs) and to apply some ice on the burning sensation areas. Few hours later, the patient was followed up and she stated her conditions had improved. On an unspecified date in Sep-2021, the patient recovered from events. The reporter did not provide a causality assessment. The case was assessed as non-serious. Company comment: A 65-year-old patient was vaccinated with Fluad Quadrivalent. One day after receiving Fluad Quadrivalent, the patient experienced rash, swelling, burning sensation and pain on left arm that was three inches below the injection site. The patient was provided with Benadryl and few hours later conditions had improved. Due to plausible temporal relationship and biological plausibility, causality is assessed as possibly related for all events; Sender's Comments: A 65-year-old patient was vaccinated with Fluad Quadrivalent. One day after receiving Fluad Quadrivalent, the patient experienced rash, swelling, burning sensation and pain on left arm that was three inches below the injection site. The patient was provided with Benadryl and few hours later conditions had improved. Due to plausible temporal relationship and biological plausibility, causality is assessed as possibly related for all events.
Sex: F
Vaccine: FLU4
Symptoms: Mobility decreased, Pain in extremity
Clinical narrative: Arm pain; It is hard to raise the arm; This spontaneous case was received on 21-Oct-2021 from a pharmacist via The Regulatory Authority (reference number: SEQW21-04341) and concerned a female patient of unreported age.  The patient's medical history and concomitant medications were not reported.  On 29-Oct-2021, the patient was vaccinated with Afluria Quadrivalent (influenza vaccine; dose 0.5 ml, route of administration: intramuscular and anatomical location: deltoid) for Influenza prophylaxis. The batch number was not reported.  On 01-Oct-2021, two days after receiving Afluria Quadrivalent, the patient experienced arm pain.  On an unknown day in Oct-2021, it was hard to patient to raise the arm.  At the time of initial reporting on 21-Oct-2021, the patient had not recovered from the events.  The reporter did not provide a causality assessment.  The reporter assessed the events as non-serious.  Company comment: A patient of an unreported age was vaccinated with Afluria Quadrivalent. Two days after receiving Afluria Quadrivalent, the patient experienced arm pain and mobility decreased. Due to biological and chronological plausibility, causality is assessed as possibly related.; Sender's Comments: A patient of an unreported age was vaccinated with Afluria Quadrivalent. Two days after receiving Afluria Quadrivalent, the patient experienced arm pain and mobility decreased. Due to biological and chronological plausibility, causality is assessed as possibly related.
Age: 45.0
Sex: M
Vaccine: FLUC3
Symptoms: No adverse event, Product storage error
Clinical narrative: Flucelvax vaccine administered to one patient following temperature excursion of 60.8ºF for 18 hours; Flucelvax vaccine administered to one patient following temperature excursion of 60.8ºF; This spontaneous case was received on 26-Oct-2021 from other healthcare professional via The Regulatory Authority (reference number: SEQW21-04597) and concerned a 45-year-old, male patient.  The patient's medical history and concomitant medications were not reported.  On an unspecified date, Flucelvax Quadrivalent vaccine (influenza vaccine, subunit influenza virus vaccine polyvalent) was exposed to  temperature of 60.8 degrees of Fahrenheit being the highest temperature reached for 18 hours (explicitly coded as 'Product storage error temperature too high'). This was a first excursion. The batch number reported was 308520 and expiry date was 30-Jun-2022.   On 26-Oct-2021, an unknown amount of time after temperature excursion, the patient was vaccinated with Flucelvax Quadrivalent (dose: 0.5 ml, route of administration: intramuscular and anatomical location: deltoid) (explicitly coded as 'Product administration error') as an influenza prophylaxis. No corrective treatment was applied.  At the time of initial reporting on 26-Oct-2021, no adverse events observed after Flucelvax Quadrivalent administration.  The reporter assessed the event as non-serious.  Company comment: Flucelvax Quadrivalent was exposed to temperature of 60.8 degrees of Fahrenheit being the highest temperature reached for 18 hours. On 26-Oct-2021, an unknown amount of time after temperature excursion, the patient was vaccinated with Flucelvax Quadrivalent. No adverse events observed after vaccine administration. Product storage error and product administration error are assessed as unrelated per company's conventions.; Sender's Comments: Flucelvax Quadrivalent was exposed to temperature of 60.8 degrees of Fahrenheit being the highest temperature reached for 18 hours. On 26-Oct-2021, an unknown amount of time after temperature excursion, the patient was vaccinated with Flucelvax Quadrivalent. No adverse events observed after vaccine administration. Product storage error and product administration error are assessed as unrelated per company's conventions.
Age: 38.0
Sex: F
Vaccine: FLUC3
Symptoms: Induration, Injection site erythema, Lymph node pain, Lymphadenopathy, Malaise
Clinical narrative: This spontaneous case was retrieved on 29-Oct-2021 from Vaccine Adverse Event Reporting System (VAERS) (reference number: 1783625-1), reported by other non-healthcare professional and concerned a 38-year-old, female patient. The patient's concurrent condition included migraine and she had no allergies. The patient's concomitant medications included Wellbutrin (bupropion hydrochloride), unspecified vitamin B, unspecified vitamin D and Zyrtec (cetirizine hydrochloride), all used for unreported indications. On 09-Oct-2021, the patient was vaccinated with Flucelvax Quadrivalent (influenza vaccine, subunit influenza virus vaccine polyvalent; dose reported as 'one', route of administration: intramuscular, anatomical location: left arm and indication: not reported). The batch number reported was 308471. On 10-Oct-2021, one day after receiving Flucelvax Quadrivalent, the patient developed redness at injection site. In addition, the patient's cervical lymph nodes were hot, hard and painful, like three rocks by her collar bone. On an unknown day in Oct-2021, the patient experienced general feelings of malaise. On 12-Oct-2021, all the lymph nodes were swollen in her armpit and it hurt to put arm at her side. Also, general feeling of malaise continued. On 13-Oct-2021, lymph nodes were still swollen and painful. The patient had never had a reaction before. No laboratory analyses were performed. At the time of this report, the patient had not recovered from the events. The reporter did not provide a causality assessment. The events were assessed as non-serious. Company comment: A 38-year-old patient was vaccinated with Flucelvax Quadrivalent. One day after receiving Flucelvax Quadrivalent, the patient developed redness at vaccination site. In addition, the patient developed general malaise and her cervical lymph nodes were hot, hard and painful. Causal role of the suspect vaccine is assessed as possibly related for all events, considering plausible time relationship.; Sender's Comments: A 38-year-old patient was vaccinated with Flucelvax Quadrivalent. One day after receiving Flucelvax Quadrivalent, the patient developed redness at vaccination site. In addition, the patient developed general malaise and her cervical lymph nodes were hot, hard and painful. Causal role of the suspect vaccine is assessed as possibly related for all events, considering plausible time relationship.
Age: 38.0
Sex: F
Vaccine: FLUC3
Symptoms: Skin warm
Clinical narrative: This spontaneous case was retrieved on 29-Oct-2021 from Vaccine Adverse Event Reporting System (VAERS) (reference number: 1783625-1), reported by other non-healthcare professional and concerned a 38-year-old, female patient. The patient's concurrent condition included migraine and she had no allergies. The patient's concomitant medications included Wellbutrin (bupropion hydrochloride), unspecified vitamin B, unspecified vitamin D and Zyrtec (cetirizine hydrochloride), all used for unreported indications. On 09-Oct-2021, the patient was vaccinated with Flucelvax Quadrivalent (influenza vaccine, subunit influenza virus vaccine polyvalent; dose reported as 'one', route of administration: intramuscular, anatomical location: left arm and indication: not reported). The batch number reported was 308471. On 10-Oct-2021, one day after receiving Flucelvax Quadrivalent, the patient developed redness at injection site. In addition, the patient's cervical lymph nodes were hot, hard and painful, like three rocks by her collar bone. On an unknown day in Oct-2021, the patient experienced general feelings of malaise. On 12-Oct-2021, all the lymph nodes were swollen in her armpit and it hurt to put arm at her side. Also, general feeling of malaise continued. On 13-Oct-2021, lymph nodes were still swollen and painful. The patient had never had a reaction before. No laboratory analyses were performed. At the time of this report, the patient had not recovered from the events. The reporter did not provide a causality assessment. The events were assessed as non-serious. Company comment: A 38-year-old patient was vaccinated with Flucelvax Quadrivalent. One day after receiving Flucelvax Quadrivalent, the patient developed redness at vaccination site. In addition, the patient developed general malaise and her cervical lymph nodes were hot, hard and painful. Causal role of the suspect vaccine is assessed as possibly related for all events, considering plausible time relationship.; Sender's Comments: A 38-year-old patient was vaccinated with Flucelvax Quadrivalent. One day after receiving Flucelvax Quadrivalent, the patient developed redness at vaccination site. In addition, the patient developed general malaise and her cervical lymph nodes were hot, hard and painful. Causal role of the suspect vaccine is assessed as possibly related for all events, considering plausible time relationship.
Age: 71.0
Sex: F
Vaccine: FLUA4
Symptoms: Dyspnoea, Throat tightness
Clinical narrative: Throat feels tight; Can hardly breathe; This spontaneous case was received on 09-Nov-2021 from other non-healthcare professional (the patient) via The Regulatory Authority (reference number: SEQW21-05224) and concerned a 71-year-old, female patient.  The patient's concurrent conditions included MS (multiple sclerosis), colitis, and allergy to sea food. The patient's concomitant medications included Anoro Ellipta (umeclidinium bromide, vilanterol trifenatate), Albuterol sulfate (salbutamol sulfate), Alendronate (alendronate sodium), amlodipine, budesonide, clonazepam, propranolol and Venlafaxine (venlafaxine hydrochloride) all used for unreported indication. The patient received Fluad Quad last year with no side effect.  On an unknown day in Sep-2021, the patient was vaccinated with Fluad Quadrivalent (Influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, mf59; dose 0.5 ml, route of administration: intramuscular and anatomical location: deltoid) for influenza prophylaxis. The batch number was not reported.  On unknown day in Sep-2021, an unknown amount of time after receiving Fluad Quadrivalent, the patient experienced a severe reaction, she could hardly breathe and her throat felt tight. The patient was treated with Anoro Ellipta (umeclidinium bromide, vilanterol trifenatate).  The outcome of the events was unknown.   The reporter assessed the events to be related to Fluad Quadrivalent.  The events were considered to be medically significant by a Physician within Seqirus' Pharmacovigilance and Risk Management Department.  Company comment: A 71-year-old, female patient developed throat tightness causing dyspnoea an unknown amount of time after vaccination with the suspect product Fluad Quadrivalent. Causality for the reported events is unassessable due to unclear chronology.; Sender's Comments: A 71-year-old, female patient developed throat tightness causing dyspnoea an unknown amount of time after vaccination with the suspect product Fluad Quadrivalent. Causality for the reported events is unassessable due to unclear chronology.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Ear pain, Lymph node pain, Oropharyngeal pain
Clinical narrative: minimal pain in left ear and throat.  A lot of pain, 7/10, in my right axillary area (lymph node pain)
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia
Clinical narrative: Systemic: Numbness (specify: facial area, extremities)-Mild
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Limb injury, Pain, Paraesthesia
Clinical narrative: Error: Shoulder Joint Injury (prolonged pain, tingling, etc.)-
Age: 20.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Condition aggravated, Dysstasia, Fatigue, Feeding disorder
Clinical narrative: Moderna COVID-19 Vaccine EUA; I felt fine until I laid down at night, immensely tired.  I was restless in my sleep and had auditory and sometimes visual hallucinations, it is now Wednesday (got the booster Monday) and I still have a relentless headache.  I was highly sensitive to anything touching my body and had immense chills.  My fever has not broken below 100 in two days.  I cannot stand up without getting a migraine.  I could not eat for a while also.  Restless when I try to sleep and fatigued when awake.
Age: 20.0
Sex: F
Vaccine: COVID19
Symptoms: Hallucination, auditory, Hallucination, visual, Headache, Hyperaesthesia, Migraine
Clinical narrative: Moderna COVID-19 Vaccine EUA; I felt fine until I laid down at night, immensely tired.  I was restless in my sleep and had auditory and sometimes visual hallucinations, it is now Wednesday (got the booster Monday) and I still have a relentless headache.  I was highly sensitive to anything touching my body and had immense chills.  My fever has not broken below 100 in two days.  I cannot stand up without getting a migraine.  I could not eat for a while also.  Restless when I try to sleep and fatigued when awake.
Age: 20.0
Sex: F
Vaccine: COVID19
Symptoms: Poor quality sleep, Pyrexia
Clinical narrative: Moderna COVID-19 Vaccine EUA; I felt fine until I laid down at night, immensely tired.  I was restless in my sleep and had auditory and sometimes visual hallucinations, it is now Wednesday (got the booster Monday) and I still have a relentless headache.  I was highly sensitive to anything touching my body and had immense chills.  My fever has not broken below 100 in two days.  I cannot stand up without getting a migraine.  I could not eat for a while also.  Restless when I try to sleep and fatigued when awake.
Age: 11.0
Sex: M
Vaccine: COVID19
Symptoms: Angina pectoris, Blood test, Chest X-ray normal, Chest pain, Crying
Clinical narrative: My woke me up at 2:30 a.m. clutching his chest, crying out in pain, saying, ?Mommy, my heart is hurting!? He couldn?t take a deep breath because of the pain. In addition, he reported severe body pain and was sobbing! I rushed him to the ER, where they did a cardiac work-up, which was unremarkable (I.e., no signs of myocarditis or pericarditis). He was given Tylenol and Ibuprofen, which helped reduce the pain. He?s had to have around the clock Tylenol and Ibuprofen since that time to cope with pain. As of last night he seemed to be feeling better and he was able to take deep breaths without pain. I have never seen my son this symptomatic from any illness or vaccine in his entire life! As an aside, he had side effects following the first dose (I.e., body pain, low grade fever, lethargy, loss of appetite). We have a follow-up with his pediatrician today.
Age: 11.0
Sex: M
Vaccine: COVID19
Symptoms: Electrocardiogram normal, Full blood count, Metabolic function test, Pain, Troponin
Clinical narrative: My woke me up at 2:30 a.m. clutching his chest, crying out in pain, saying, ?Mommy, my heart is hurting!? He couldn?t take a deep breath because of the pain. In addition, he reported severe body pain and was sobbing! I rushed him to the ER, where they did a cardiac work-up, which was unremarkable (I.e., no signs of myocarditis or pericarditis). He was given Tylenol and Ibuprofen, which helped reduce the pain. He?s had to have around the clock Tylenol and Ibuprofen since that time to cope with pain. As of last night he seemed to be feeling better and he was able to take deep breaths without pain. I have never seen my son this symptomatic from any illness or vaccine in his entire life! As an aside, he had side effects following the first dose (I.e., body pain, low grade fever, lethargy, loss of appetite). We have a follow-up with his pediatrician today.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site bruising
Clinical narrative: Site: Bruising at Injection Site-Mild
Age: 96.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, COVID-19 pneumonia, Chest X-ray abnormal, Dyspnoea
Clinical narrative: Hospitalized 11/20/2021; COVID-19 positive 11/13/2021; fully vaccinated  BRIEF OVERVIEW:  Admission Date: 11/20/2021 Discharge Date: Nov 24, 2021 DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: COVID [U07.1] COVID-19 [U07.1] Generalized weakness [R53.1] HOSPITAL COURSE: Patient is a 97-year-old male with a past medical history of hypertension, CVA on Eliquis, CKD stage 3, diabetes mellitus type 2, dyslipidemia BPH who presented from his independent living facility with generalized weakness.  He had 6 days of progressive weakness prior to admission.  This included an assisted fall to the ground by family.  He did not hit his head or lose consciousness.  He also complained of shortness of breath and ?brain fog ?.  He tested positive for COVID-19 on November 13, 2021. He was fully vaccinated with Moderna vaccine.  He was febrile in the emergency department at 38.3.  Otherwise his vital signs were unremarkable.  Chest x-ray showed bilateral patchy opacities consistent with COVID-19 pneumonia.  He was not hypoxic.  He was placed in observation status initially.  He did qualify for monoclonal antibodies.  He received this and tolerated it well.  He did not qualify for Decadron or remdesivir as he was not hypoxic.  The patient's weakness persisted.  PT/OT recommended acute rehab.  He was discharged to acute rehab on 11/24/2021.  Rehab admission note 11/24/2021: HISTORY OF PRESENT ILLNESS: History was obtained from the patient as well as extensive chart review which is highlighted and summarized below   97 y.o. male with pmh of Carotid artery disease, CKD 3, GERD, HTN, HLD, peripheral neuropathy, hx of CVA, aortic arch thrombus who was admitted with progressive weakness, sob and brain fog found to be secondary to covid pneumonia. Patient tested positive on 11/15, patient is fully vaccinated. He was febrile on admission.  Patient had XR that showed patchy opacities in bilateral bases and left mid lung consistent with covid pneumonia. He was not a candidate for decadron, or remdesivir as he was no hypoxic. He did get monoclonal antibody therapy and tolerated it well. His hospital stay was otherwise uncomplicated though he is quite debilitated and deconditioned.   Prior to  hospitalization the patient was functionally independent with mobility and ADLs. Since his hospitalization he has had a functional decline to where he is now requiring mion assist bathing, transfers and ambulation. Due to his functional decline he will be admitted to inpatient rehab.
Age: 96.0
Sex: M
Vaccine: COVID19
Symptoms: Fall, Feeling abnormal, Loss of personal independence in daily activities, Lung opacity, Physical deconditioning
Clinical narrative: Hospitalized 11/20/2021; COVID-19 positive 11/13/2021; fully vaccinated  BRIEF OVERVIEW:  Admission Date: 11/20/2021 Discharge Date: Nov 24, 2021 DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: COVID [U07.1] COVID-19 [U07.1] Generalized weakness [R53.1] HOSPITAL COURSE: Patient is a 97-year-old male with a past medical history of hypertension, CVA on Eliquis, CKD stage 3, diabetes mellitus type 2, dyslipidemia BPH who presented from his independent living facility with generalized weakness.  He had 6 days of progressive weakness prior to admission.  This included an assisted fall to the ground by family.  He did not hit his head or lose consciousness.  He also complained of shortness of breath and ?brain fog ?.  He tested positive for COVID-19 on November 13, 2021. He was fully vaccinated with Moderna vaccine.  He was febrile in the emergency department at 38.3.  Otherwise his vital signs were unremarkable.  Chest x-ray showed bilateral patchy opacities consistent with COVID-19 pneumonia.  He was not hypoxic.  He was placed in observation status initially.  He did qualify for monoclonal antibodies.  He received this and tolerated it well.  He did not qualify for Decadron or remdesivir as he was not hypoxic.  The patient's weakness persisted.  PT/OT recommended acute rehab.  He was discharged to acute rehab on 11/24/2021.  Rehab admission note 11/24/2021: HISTORY OF PRESENT ILLNESS: History was obtained from the patient as well as extensive chart review which is highlighted and summarized below   97 y.o. male with pmh of Carotid artery disease, CKD 3, GERD, HTN, HLD, peripheral neuropathy, hx of CVA, aortic arch thrombus who was admitted with progressive weakness, sob and brain fog found to be secondary to covid pneumonia. Patient tested positive on 11/15, patient is fully vaccinated. He was febrile on admission.  Patient had XR that showed patchy opacities in bilateral bases and left mid lung consistent with covid pneumonia. He was not a candidate for decadron, or remdesivir as he was no hypoxic. He did get monoclonal antibody therapy and tolerated it well. His hospital stay was otherwise uncomplicated though he is quite debilitated and deconditioned.   Prior to  hospitalization the patient was functionally independent with mobility and ADLs. Since his hospitalization he has had a functional decline to where he is now requiring mion assist bathing, transfers and ambulation. Due to his functional decline he will be admitted to inpatient rehab.
Age: 96.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 test positive
Clinical narrative: Hospitalized 11/20/2021; COVID-19 positive 11/13/2021; fully vaccinated  BRIEF OVERVIEW:  Admission Date: 11/20/2021 Discharge Date: Nov 24, 2021 DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: COVID [U07.1] COVID-19 [U07.1] Generalized weakness [R53.1] HOSPITAL COURSE: Patient is a 97-year-old male with a past medical history of hypertension, CVA on Eliquis, CKD stage 3, diabetes mellitus type 2, dyslipidemia BPH who presented from his independent living facility with generalized weakness.  He had 6 days of progressive weakness prior to admission.  This included an assisted fall to the ground by family.  He did not hit his head or lose consciousness.  He also complained of shortness of breath and ?brain fog ?.  He tested positive for COVID-19 on November 13, 2021. He was fully vaccinated with Moderna vaccine.  He was febrile in the emergency department at 38.3.  Otherwise his vital signs were unremarkable.  Chest x-ray showed bilateral patchy opacities consistent with COVID-19 pneumonia.  He was not hypoxic.  He was placed in observation status initially.  He did qualify for monoclonal antibodies.  He received this and tolerated it well.  He did not qualify for Decadron or remdesivir as he was not hypoxic.  The patient's weakness persisted.  PT/OT recommended acute rehab.  He was discharged to acute rehab on 11/24/2021.  Rehab admission note 11/24/2021: HISTORY OF PRESENT ILLNESS: History was obtained from the patient as well as extensive chart review which is highlighted and summarized below   97 y.o. male with pmh of Carotid artery disease, CKD 3, GERD, HTN, HLD, peripheral neuropathy, hx of CVA, aortic arch thrombus who was admitted with progressive weakness, sob and brain fog found to be secondary to covid pneumonia. Patient tested positive on 11/15, patient is fully vaccinated. He was febrile on admission.  Patient had XR that showed patchy opacities in bilateral bases and left mid lung consistent with covid pneumonia. He was not a candidate for decadron, or remdesivir as he was no hypoxic. He did get monoclonal antibody therapy and tolerated it well. His hospital stay was otherwise uncomplicated though he is quite debilitated and deconditioned.   Prior to  hospitalization the patient was functionally independent with mobility and ADLs. Since his hospitalization he has had a functional decline to where he is now requiring mion assist bathing, transfers and ambulation. Due to his functional decline he will be admitted to inpatient rehab.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Incorrect route of product administration
Clinical narrative: Error: Wrong Route (SC, IM, etc.)-
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Cough, Fatigue, Pain, Respiratory tract congestion
Clinical narrative: COUGH, FATIUGE, BODY ACHES, CHEST CONGESTION
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: COUGH, FATIUGE, BODY ACHES, CHEST CONGESTION
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pain
Clinical narrative: Site: Pain at Injection Site-Medium
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Pain, Pain in extremity, Sinus congestion
Clinical narrative: The same day, my sinuses closed up and I had body aches and my hands hurt really bad. The next day, I still had the body aches, but also got a bad cough, and developed a temperature of 99.5 degrees.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Injection site pain
Clinical narrative: Site: Pain at Injection Site-Medium
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Hyperhidrosis, Nausea
Clinical narrative: Fever 100 Chills / sweats Nausea Headache  Fatigue
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Fever 100 Chills / sweats Nausea Headache  Fatigue
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, Headache, Lethargy, Surgery, Ultrasound scan abnormal
Clinical narrative: Within 1 month of receiving the vaccination, a varicose vein began to form on my left leg. Within weeks of it first appearing, the vein spread in a spiderweb-like fashion, surrounding my shin region. Within another month, the pain and sensation caused by the varicose vein was severe to the point that everyday functioning was not possible without use of a compression stocking. After doctor consultation, surgery was recommended to remove the vein. A pre-surgery sonogram of my legs determined that other varicose veins have started to form internally throughout my lower body, and will need to be monitored. Surgery was performed on Nov. 11th.   My family does have a history of varicose veins, and I have had one removed in the past. But unlike the previous surgery, I'm suffering from regular headaches, dizziness and lethargy post-surgery. Pre-surgical testing from the previous procedure also did not show other internal varicose veins forming.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Varicose vein, Vascular pain
Clinical narrative: Within 1 month of receiving the vaccination, a varicose vein began to form on my left leg. Within weeks of it first appearing, the vein spread in a spiderweb-like fashion, surrounding my shin region. Within another month, the pain and sensation caused by the varicose vein was severe to the point that everyday functioning was not possible without use of a compression stocking. After doctor consultation, surgery was recommended to remove the vein. A pre-surgery sonogram of my legs determined that other varicose veins have started to form internally throughout my lower body, and will need to be monitored. Surgery was performed on Nov. 11th.   My family does have a history of varicose veins, and I have had one removed in the past. But unlike the previous surgery, I'm suffering from regular headaches, dizziness and lethargy post-surgery. Pre-surgical testing from the previous procedure also did not show other internal varicose veins forming.
Age: 6.0
Sex: F
Vaccine: COVID19
Symptoms: Product preparation issue
Clinical narrative: Error: Wrong Vaccine Formulation  (ex. different manufact. initial and booster)-
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Headache, Pyrexia
Clinical narrative: Fever, chills, headache, joint pain
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood creatinine increased, Glomerular filtration rate decreased, Renal impairment
Clinical narrative: 4 days after second dose a routine blood test showed a reduction in my kidney function.
Age: 80.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acute respiratory failure, Atrial fibrillation, COVID-19, COVID-19 pneumonia, Cardiac failure congestive
Clinical narrative: Hospitalized 11/21/2021; COVID-19 positive 11/21/2021; fully vaccinated  DATE OF ADMISSION:  11/21/2021 DATE OF DISCHARGE:  11/25/2021  DISCHARGE DIAGNOSES 1. Severe COVID pneumonia with acute hypoxic respiratory failure (this is a correction to documentation elsewhere in the chart, which did not say pneumonia.  Chest x-ray does show pneumonia.). 2. Chronic diastolic congestive heart failure. 3. Monoclonal gammopathy. 4. Paroxysmal atrial fibrillation. 5. Obstructive sleep apnea. 6. Morbid obesity. 7. Hyperlipidemia. 8. Gout. HOSPITAL COURSE An 80-year-old gentleman presented to the emergency room with increasing shortness of breath and dyspnea on exertion.  See H and P for full details.  In the ER, he was tachypneic and using accessory muscles of respiration.  COVID positive.  Chest x-ray showed interstitial infiltrates.  He was admitted and started on Solu-Medrol and Remdesivir.  Completed 5 doses of Remdesivir.  Solu-Medrol tapered over the course of the hospitalization.  Treated with IV Lasix, although his peripheral edema did not change much.  I's and O's were not accurate.  On the day of discharge, the patient was able to ambulate around the room on his home 3 L with O2 saturations staying in the mid 90s.  He felt stable for discharge.  Only minimal dyspnea on exertion was present, but he stated was at his baseline.
Age: 80.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chest X-ray abnormal, Chronic left ventricular failure, Condition aggravated, Dyspnoea, Dyspnoea exertional
Clinical narrative: Hospitalized 11/21/2021; COVID-19 positive 11/21/2021; fully vaccinated  DATE OF ADMISSION:  11/21/2021 DATE OF DISCHARGE:  11/25/2021  DISCHARGE DIAGNOSES 1. Severe COVID pneumonia with acute hypoxic respiratory failure (this is a correction to documentation elsewhere in the chart, which did not say pneumonia.  Chest x-ray does show pneumonia.). 2. Chronic diastolic congestive heart failure. 3. Monoclonal gammopathy. 4. Paroxysmal atrial fibrillation. 5. Obstructive sleep apnea. 6. Morbid obesity. 7. Hyperlipidemia. 8. Gout. HOSPITAL COURSE An 80-year-old gentleman presented to the emergency room with increasing shortness of breath and dyspnea on exertion.  See H and P for full details.  In the ER, he was tachypneic and using accessory muscles of respiration.  COVID positive.  Chest x-ray showed interstitial infiltrates.  He was admitted and started on Solu-Medrol and Remdesivir.  Completed 5 doses of Remdesivir.  Solu-Medrol tapered over the course of the hospitalization.  Treated with IV Lasix, although his peripheral edema did not change much.  I's and O's were not accurate.  On the day of discharge, the patient was able to ambulate around the room on his home 3 L with O2 saturations staying in the mid 90s.  He felt stable for discharge.  Only minimal dyspnea on exertion was present, but he stated was at his baseline.
Age: 80.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Gout, Hyperlipidaemia, Lung infiltration, Monoclonal gammopathy, Obesity
Clinical narrative: Hospitalized 11/21/2021; COVID-19 positive 11/21/2021; fully vaccinated  DATE OF ADMISSION:  11/21/2021 DATE OF DISCHARGE:  11/25/2021  DISCHARGE DIAGNOSES 1. Severe COVID pneumonia with acute hypoxic respiratory failure (this is a correction to documentation elsewhere in the chart, which did not say pneumonia.  Chest x-ray does show pneumonia.). 2. Chronic diastolic congestive heart failure. 3. Monoclonal gammopathy. 4. Paroxysmal atrial fibrillation. 5. Obstructive sleep apnea. 6. Morbid obesity. 7. Hyperlipidemia. 8. Gout. HOSPITAL COURSE An 80-year-old gentleman presented to the emergency room with increasing shortness of breath and dyspnea on exertion.  See H and P for full details.  In the ER, he was tachypneic and using accessory muscles of respiration.  COVID positive.  Chest x-ray showed interstitial infiltrates.  He was admitted and started on Solu-Medrol and Remdesivir.  Completed 5 doses of Remdesivir.  Solu-Medrol tapered over the course of the hospitalization.  Treated with IV Lasix, although his peripheral edema did not change much.  I's and O's were not accurate.  On the day of discharge, the patient was able to ambulate around the room on his home 3 L with O2 saturations staying in the mid 90s.  He felt stable for discharge.  Only minimal dyspnea on exertion was present, but he stated was at his baseline.